HHC banned in France: the 2022-2026 timeline

HHC is a hydrogenated version of THC: hydrogen atoms are added to a THC-type molecule. It was first described in 1940 but only reached the market recently. According to a 2025 study in Pharmacology Research & Perspectives, it is most often made from cannabidiol, or by reducing THC or Δ⁸-THC. That is why it is called semi-synthetic: the starting material comes from hemp, the final molecule comes out of a reactor.

HHC exists in two forms, labelled 9R and 9S. The 9R form binds more strongly to the brain's cannabinoid receptors, the same ones THC activates. HHC therefore has a psychoactive effect close to that of cannabis. This is the basic difference from CBD, which has no such effect; our article does CBD get you high explains why.

It first benefited from a legal gap: no text named it. For a year, shops and websites sold it openly, often on the CBD shelf.

The HHC market was built in a few months, and the regulatory response followed each wave of replacement molecules.

The 2024 decision is not just a list of names. It covers the whole family of benzo[c]chromene derivatives, the chemical backbone shared by THC and HHC, plus several fully synthetic cannabinoids. The aim is to stop a variant with one atom changed from slipping through. THCA is on the list, but the ANSM specifies that it is not covered when it comes from hemp whose THC content meets the 0.3% threshold. Our page on THCA covers this often misunderstood point.

The agency gives three reasons in its decision of 12 June 2023. HHC carries "a risk of abuse and dependence equivalent to that of cannabis". Its chemical structure is close to that of Δ⁹-THC. And it is sometimes consumed "without the knowledge of users who think they are consuming another product, such as CBD".

In 2024, the ANSM listed the serious effects reported by addiction monitoring centres after use of the replacement molecules: vomiting, loss of consciousness, seizures, anxiety, high blood pressure and a racing heart.

Czech data give a sense of scale. Between May 2022 and April 2024, the toxicology information centre in Prague counted 196 poisoning cases, 185 with HHC and 11 with HHCP. Symptoms were neurological in 74% of cases, mostly drowsiness, tremor and dizziness. Thirty-nine patients were under 15, or 19% of cases. Where the product was known, 38% of cases involved gummies and 35% cigarettes, joints or vapes. Cases fell after the Czech ban of 1 March 2024, while those linked to HHCP, still allowed at the time, rose slightly.

This pattern, a molecule that is legal by omission followed by ever less studied replacements, echoes the story of synthetic cannabinoids. We trace that history in our article on synthetic cannabinoids and harm reduction.

Classification makes HHC a controlled drug like any other. Production, sale, transport, possession, purchase and use are banned in France. Article L3421-1 of the French Public Health Code punishes use with one year in prison and a €3,750 fine. Since Law no. 2026-798 of 18 August 2026, in force on 20 August, prosecution can be settled with a €500 fixed fine, reduced to €400 for prompt payment and raised to €1,000 for late payment.

Selling falls under drug trafficking, which is punished far more heavily. And driving after using a controlled substance falls under article L235-1 of the French Highway Code, which provides for up to 3 years in prison and a €9,000 fine; our article on CBD and driving explains this regime.

The same reasoning applies to HHC's successors. Our pages on H4-CBD and THCP describe these molecules one by one.

A product sold as CBD should never promise a high. If it does, either it exceeds the THC threshold or it contains a controlled cannabinoid. Four simple checks:

1. The label: HHC, HHC-O, HHC-P, HHCPO, H4-CBD, THCP or any unfamiliar abbreviation is enough to rule the product out.
2. The promise: "powerful effect", "legal alternative to THC" or a name that suggests intoxication has no place on a CBD product.
3. The certificate of analysis: it must carry the batch number of the product sold and a Δ⁹-THC level of 0.3% at most. Ask whether the lab looked for semi-synthetic cannabinoids: a standard analysis does not always search for them.
4. The format: in the poisonings recorded in the Czech Republic, gummies and products to smoke or vape dominated. Nothing visible distinguishes an HHC gummy from a CBD gummy.

Our guide explains how to read a certificate of analysis, and the laboratory page describes the measurement methods. The threshold itself is covered in our article on the legal THC level.